Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder often diagnosed in school-age children that frequently persists into adulthood.1 Pharmacologic treatment of ADHD has been associated with reduced risks of substance abuse, criminal behavior, unintentional injuries, serious traffic accidents, and all-cause mortality.2-5 Drugs approved by the FDA for treatment of ADHD are listed in Table 1.
Parent Training in Behavior Management (PTBM) and...
- Clesrovimab (Enflonsia) for Prevention of Severe RSV Infection in Infants
- Mepolizumab (Nucala) for COPD
- Lenacapavir (Yeztugo) for HIV Pre-Exposure Prophylaxis
- In Brief: A New Donanemab (Kisunla) Dosing Regimen for Alzheimer's Disease
- In Brief: Pruritus Following Antihistamine Discontinuation
- In Brief: New Warning for Extended-Release Stimulants for ADHD
- In Brief: Hyperthermia with Scopolamine Patches
- Linvoseltamab (Lynozyfic) for Multiple Myeloma (online only)
ISSUE
The FDA has approved clesrovimab-cfor (Enflonsia – Merck), a long-acting monoclonal antibody, for prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants born during or entering their first RSV season. Clesrovimab is the second drug to be approved for this indication; nirsevimab (Beyfortus), another long-acting monoclonal antibody, was the first. Palivizumab (Synagis), a shorter-acting antibody, is FDA-approved for prevention of severe RSV LRTI in certain high-risk children ≤24 months old.1
RSV INFECTION — RSV typically causes a mild upper respiratory tract infection in children and adults, but it can cause severe disease and death. Young children have an increased risk of severe disease; in the US, RSV infections cause an estimated 58,000-80,000 hospitalizations each year in children <5 years …